Carmellose sodium; hypromellose

PBAC's latest decision on Carmellose sodium; hypromellose: Recommended with restriction (2019). Considered for Treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.

Eligible population

Adults with severe dry eye syndrome who are sensitive to preservatives in multi-dose eye drops.

Therapy area

Ophthalmology

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

lowest cost multi-dose preservative-free eye drops (hyaluronic acid, perfluorohexyloctane, single-dose carmellose/hypromellose)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated. No formal economic analysis presented in the minor resubmission.

Submission history

• Jul 2018: Recommended with restriction · Authority Required
• Jul 2019: Recommended with restriction · Authority Required

Similar precedents

• Cationic ophthalmic emulsion, preservative free
  similarity 0.83
• Hyaluronic acid with polyethylene glycol 400 with propylene glycol with hydroxypropyl guar
  similarity 0.80
• Carmellose sodium with glycerol and hyaluronic acid
  similarity 0.80
• Ocular lubricants (multiple active ingredients)
  similarity 0.81
• Hypromellose
  similarity 0.78
• Perfluorohexyloctane
  similarity 0.76